Imunon, Inc. (LON: 0HUZ)
London
· Delayed Price · Currency is GBP · Price in USD
0.880
-0.051 (-5.44%)
Jan 29, 2025, 2:56 PM BST
Imunon Employees
Imunon had 33 employees as of December 31, 2023. The number of employees increased by 2 or 6.45% compared to the previous year.
Employees
33
Change (1Y)
2
Growth (1Y)
6.45%
Revenue / Employee
n/a
Profits / Employee
-439.77K GBP
Market Cap
10.32M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
AstraZeneca | 89,900 |
GSK plc | 70,212 |
Haleon | 25,408 |
Smith & Nephew | 18,452 |
Hikma Pharmaceuticals | 9,100 |
ConvaTec Group | 10,136 |
HUTCHMED (China) | 1,988 |
Oxford Nanopore Technologies | 1,238 |
Imunon News
- 6 weeks ago - IMUNON Announces Positive CMC Meeting with FDA for IMNN-001 in Treatment of Advanced Ovarian Cancer - GlobeNewsWire
- 7 weeks ago - IMUNON Announces Continued Strong Improvement in Overall Survival Data from Randomized Phase 2 OVATION 2 Study of IMNN-001 - GlobeNewsWire
- 2 months ago - IMUNON Announces Results from its End-of-Phase 2 Meeting with the FDA for its Lead IMNN-001 Clinical Program in Advanced Ovarian Cancer - GlobeNewsWire
- 3 months ago - Imunon, Inc. (IMNN) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 3 months ago - IMUNON Presents Positive Data from Phase 2 OVATION 2 Clinical Trial of IMNN-001 in Advanced Ovarian Cancer at SITC 39th Annual Meeting - GlobeNewsWire
- 3 months ago - IMUNON Reports Third Quarter 2024 Financial Results and Provides Business Updates - GlobeNewsWire
- 3 months ago - IMUNON to Hold Third Quarter 2024 Financial Results and Business Update Conference Call on Thursday, November 7, 2024 - GlobeNewsWire
- 3 months ago - IMUNON to Present Phase 2 Data of IMNN-001 in Treatment of Newly Diagnosed Ovarian Cancer at SITC 39th Annual Meeting - GlobeNewsWire